|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
somatostatin analog
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1998
gptkb:United_States
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
severe liver disease
pancreatitis
gallbladder disease
hypersensitivity to octreotide
|
|
gptkbp:financial_products
|
D B00501
|
|
gptkbp:formulation
|
injectable solution
long-acting release
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sandostatin
|
|
gptkbp:indication
|
neuroendocrine tumors
esophageal variceal bleeding
|
|
gptkbp:ingredients
|
gptkb:octreotide
|
|
gptkbp:interacts_with
|
gptkb:Company
glucagon
growth hormone
somatostatin receptors
|
|
gptkbp:invention
|
gptkb:2018
|
|
gptkbp:is_atype_of
|
H01 C B02
|
|
gptkbp:is_available_on
|
gptkb:Sandostatin_LAR
Sandostatin injection
|
|
gptkbp:is_used_for
|
acromegaly
VI Poma
carcinoid syndrome
|
|
gptkbp:lifespan
|
1.5 to 2 hours
|
|
gptkbp:manager
|
subcutaneous injection
intravenous injection
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:India
gptkb:Japan
gptkb:Native_American_tribe
|
|
gptkbp:monitors
|
0 D1 B2 D1 B2 D
|
|
gptkbp:rounds
|
biliary
renal
|
|
gptkbp:side_effect
|
fatigue
nausea
abdominal pain
diarrhea
gallstones
|
|
gptkbp:social_structure
|
C49 H66 N10 O10 S
|
|
gptkbp:storage
|
refrigerated
protected from light
|
|
gptkbp:type_of
|
79517-01-4
|
|
gptkbp:bfsParent
|
gptkb:octreotide
|
|
gptkbp:bfsLayer
|
7
|